Mucosal Vaccines: Advances in Technology and Delivery
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 5
Special Issue Editor
Interests: vaccine; adjuvanted vanncine; microspheres/nanoparticle; vaccine delivery system; intranasal delivery; mucosal immunity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mucosal vaccines are an attractive immunization platform with long-term local immune response and improved immunogenicity. As mucosal surfaces serve as the initial contact points for numerous pathogens, they present a unique avenue for immunological engagement. Mucosal vaccines can induce mucosal immune responses, preventing infectious pathogens from attaching and colonizing mucosal epithelia and stopping invasive bacteria and viruses from penetrating and replicating within the mucosa. Mucosal vaccines have several advantages, including their non-invasive nature and not requiring injections, which reduces physical and psychological discomfort for patients, increases patients’ willingness to accept the vaccine, and improves safety.
This Special Issue focuses on presenting an exhaustive synopsis of the latest technological progress and delivery methodologies that augment mucosal vaccines' potency and safety profiles. By highlighting groundbreaking research—encompassing novel vaccines and adjuvants, delivery platforms, and immune-stimulating formulations—this Special Issue endeavors to deepen the comprehension of mucosal immune mechanisms and further novel developments in vaccine delivery systems for mucosal immunization.
Prof. Dr. Kai Zhao
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mucosal immunization
- mucosal vaccine
- adjuvant
- vaccine delivery strategy
- vaccine formulations
- immune response
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
